Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06543823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SUPRATHEL 250 as a Treatment for Oropharyngeal Wounds

StatusRecruiting
PhaseNot applicable
SponsorAlaa Emara
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Dec 2025 → Nov 30, 2026
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Alaa Emara

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2025 to Nov 30, 2026v4 Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Phase changed: Phase 1/2 → not applicable
    • Enrollment increased: 60 → 80 participants
    • Study completion pushed from Feb 2026 to Apr 2027
    • Interventions: Comparator (Other), SupraTHEL 250 (Device) to Comparator (Other), Suprathel 250 (Device)
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoint revised
    • Study description revised
    • Study site revised
    • Study title shortened, about 2 words
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: May 2026 to Dec 2025
    • Study completion date: Aug 2026 to Feb 2026
    • Start date changed from estimate of Jul 2025 to Apr 30, 2025
  3. Primary completion date: May 2025 to May 2026
    • Start date: Sep 2024 to Jul 2025
    • Study completion date: May 2025 to Aug 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Alaa Emara
2 trials monitored
See 1 trial at risk
To assess the use of Suprathel 250 for mucosal reconstruction in oropharyngeal defects. The membrane will be applied after tonsillectomy procedures and compared to bare wounds' healing
Trial Details
NCT Number NCT06543823
Lead Sponsor Alaa Emara
Conditions
(from sponsor)		 Tonsillitis, Tonsillectomy, Tonsillitis Recurrent
Related terms Tonsillitis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov